1. Dose‐dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity. Issue 7 (12th March 2020) Authors: Yokote, Koutaro; Sano, Misako; Tsumiyama, Isao; Keefe, Deborah Journal: Diabetes, obesity & metabolism Issue: Volume 22:Issue 7(2020) Page Start: 1102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. Issue 7 (10th March 2020) Authors: de Boer, Rudolf A.; Núñez, Julio; Kozlovski, Plamen; Wang, Yi; Proot, Pieter; Keefe, Deborah Journal: British journal of clinical pharmacology Issue: Volume 86:Issue 7(2020) Page Start: 1346 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. (3rd April 2022) Authors: Sigurgeirsson, Bardur; Schäkel, Knut; Hong, Chih-Ho; Effendy, Isaak; Placek, Waldemar; Rich, Phoebe; Keefe, Deborah; Bruin, Gerard; Charef, Pascal; Fu, Rong; Hampele, Isabelle; Patekar, Manmath Journal: Journal of dermatological treatment Issue: Volume 33:Number 3(2022) Page Start: 1718 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. Issue 5 (18th March 2020) Authors: Bays, Harold E.; Kozlovski, Plamen; Shao, Qing; Proot, Pieter; Keefe, Deborah Journal: Obesity Issue: Volume 28:Issue 5(2020) Page Start: 870 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Pharmacokinetics, Safety Profile, and Efficacy of Aliskiren in Pediatric Patients With Hypertension. (July 2013) Authors: Sullivan, Janice E.; Keefe, Deborah; Zhou, Yinong; Satlin, Lisa; Fang, Hui; Yan, Jing-He Journal: Clinical pediatrics Issue: Volume 52:Number 7(2013) Page Start: 599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial. Issue 3 (8th January 2022) Authors: Sigurgeirsson, Bardur; Browning, John; Tyring, Stephen; Szepietowski, Jacek C.; Rivera‐Díaz, Raquel; Effendy, Isaak; Keefe, Deborah; Bruin, Gerard; Paguet, Bertrand; Fu, Rong; Hampele, Isabelle; Reinhardt, Maximilian; Patekar, Manmath Journal: Dermatologic therapy Issue: Volume 35:Issue 3(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. (1st June 2022) Authors: Augustin, Matthias; Reich, Kristian; Yamauchi, Paul; Pinter, Andreas; Bagel, Jerry; Dahale, Swapnil; You, Ruquan; Bruin, Gerard; Djimopoulos, Jimena; Paguet, Bertrand; Charef, Pascal; Patekar, Manmath; Keefe, Deborah Journal: British journal of dermatology Issue: Volume 186:Number 6(2022) Page Start: 942 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. (8th April 2022) Authors: Augustin, Matthias; Reich, Kristian; Yamauchi, Paul; Pinter, Andreas; Bagel, Jerry; Dahale, Swapnil; You, Ruquan; Bruin, Gerard; Djimopoulos, Jimena; Paguet, Bertrand; Charef, Pascal; Patekar, Manmath; Keefe, Deborah Journal: British journal of dermatology Issue: Volume 186:Number 6(2022) Page Start: 942 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Issue 10378 (4th March 2023) Authors: Kimball, Alexa B; Jemec, Gregor B E; Alavi, Afsaneh; Reguiai, Ziad; Gottlieb, Alice B; Bechara, Falk G; Paul, Carle; Giamarellos Bourboulis, Evangelos J; Villani, Axel P; Schwinn, Andreas; Ruëff, Franziska; Pillay Ramaya, Larisha; Reich, Adam; Lobo, Ines; Sinclair, Rodney; Passeron, Thierry; Mart... Journal: Lancet Issue: Volume 401:Issue 10378(2023) Page Start: 747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗